Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 275-031-8 | CAS number: 70942-01-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From October 25 to November 15, 1978.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted according to internationally accepted testing guidelines, well documented and the results scientifically acceptable.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 979
- Report date:
- 1979
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- The acute oral toxicity in rats of both sexes was tested administrating the test item by gavage at doses of 7000, 8000 and 10000 mg/kg bw. The observation period following administration was of 14 days.
- GLP compliance:
- no
- Remarks:
- pre GLP
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Potassium sodium 4,4'-bis[6-anilino-4-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- EC Number:
- 275-031-8
- EC Name:
- Potassium sodium 4,4'-bis[6-anilino-4-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
- Cas Number:
- 70942-01-7
- Molecular formula:
- C40H44KN12NaO10S2
- IUPAC Name:
- potassium sodium 2,2'-ethene-1,2-diylbis[5-({4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl}amino)benzenesulfonate]
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Tif: RAIf (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 7 to 8 weeks old.
- Housing: housed in groups of 5 in Macrolon cages (type 3).
- Fasting period before study: animals fasted overnight.
- Diet: ad libitum rat food - NAFAG, Gossau SG.
- Water: ad libitum
- Acclimation period: minimum of 4 days.
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 1 °C
- Humidity: 55 ± 5 %
- Photoperiod: 10 light cycle day.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Doses:
- 7000, 8500 and 10000 mg/kg
- No. of animals per sex per dose:
- 5 males and 5 females per dose
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: recorded at day 1, 7 and 14.
- Necropsy of survivors performed: yes; the animals were submitted at random to a necropsy at the end of the observation period.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 200 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- No mortality occurred.
- Clinical signs:
- other: The rats in all dosage groups showed sedation, dyspnoea, exophthalmos, salivation and curved position; ruffled fur was observed at doses of 8500 and 10000 mg/kg bw. All symptoms were recovered within 10 days.
- Gross pathology:
- No substance related gross organ changes were seen.
Any other information on results incl. tables
Rate of deaths
Dose mg/kg |
Sex | Total Number animals in group |
Total Number animals dead |
Death rate percentage |
7000 | M | 5 | 0 | 0 |
8500 | M | 5 | 0 | 0 |
10000 | M | 5 | 0 | 0 |
7000 | F | 5 | 0 | 0 |
8500 | F | 5 | 0 | 0 |
10000 | F | 5 | 0 | 0 |
Signs and symptoms, dose of 7000 mg/kg
Signs and symptoms | hrs | Days | ||||||||||||||||
1 | 2 | 4 | 6 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | ||||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | ||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | + | + | + | + | + | |||||||||||||
Salivation | + | + | + | + | + | + | + | + | + | + | ||||||||
Ruffled fur | ||||||||||||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | + | ||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
Signs and symptoms, dose of 8500 mg/kg
Signs and symptoms | hrs | Days | ||||||||||||||||
1 | 2 | 4 | 6 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | ||||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | ||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | + | + | + | + | + | |||||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | + | + | + | + | ||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | + | ||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
Signs and symptoms, dose of 10000 mg/kg
Signs and symptoms | hrs | Days | ||||||||||||||||
1 | 2 | 4 | 6 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | + | ||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | ||||||||||
Dacryorrhoea | ||||||||||||||||||
Chromodacryorrhoea | ||||||||||||||||||
Rinorrhoea | ||||||||||||||||||
Epistaxis | ||||||||||||||||||
Exophthalmos | + | + | + | + | + | |||||||||||||
Salivation | ||||||||||||||||||
Ruffled fur | + | + | + | + | + | + | + | + | + | |||||||||
Pallor | ||||||||||||||||||
Cyanosis | ||||||||||||||||||
Diarrhoea | ||||||||||||||||||
Body position (ventral) | ||||||||||||||||||
Body position (lateral) | ||||||||||||||||||
Body position (curved) | + | + | + | + | + | + | + | + | + | |||||||||
Ataxia | ||||||||||||||||||
Trismus | ||||||||||||||||||
Tremor | ||||||||||||||||||
Tonic clonic muscle spasms | ||||||||||||||||||
Convulsions |
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information according to the CLP Regulation Criteria used for interpretation of results: EU
- Conclusions:
- LD50 > 2200 mg/kg bw
- Executive summary:
Method
The acute oral toxicity in rats of both sexes was tested administrating the test item by gavage at doses of 7000, 8000 and 10000 mg/kg bw. The observation period following administration was of 14 days.
Results
LD50 > 2200 mg/kg bw based on active ingredient.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.